Expert Talent Acquisition Orna Therapeutics has demonstrated a strategic focus on talent acquisition, evidenced by appointing esteemed professionals like Nobel Laureate Carolyn Bertozzi to its Scientific Advisory Board and experienced leaders like Frank Neumann, M.D., Ph.D., as Chief Medical Officer. Leveraging such expert talent can enhance credibility and open doors for collaborations or partnerships.
Strategic Acquisitions The recent acquisition of Renagadetx signifies Orna Therapeutics' growth strategy and interest in expanding its portfolio in the biotechnology sector. Identifying potential synergies in acquired companies can present sales opportunities to introduce Orna's innovative circular RNA technology to a broader audience.
International Collaborations Collaborations with companies like BioSpace, Inc. and Shanghai Xianbo Biotech demonstrate Orna Therapeutics' global outreach and interest in partnering to develop therapeutics, particularly in the oncology sector. These partnerships can create avenues for international sales and market penetration, tapping into new regions and markets.
Pharmaceutical Partnerships Partnering with pharmaceutical giants like Merck for developing vaccines and therapeutics in infectious disease and oncology areas highlights Orna Therapeutics' engagement with industry leaders. Such collaborations can lead to joint sales initiatives, leveraging the credibility and reach of established pharmaceutical companies.
Industry Recognition Receiving prestigious awards like the Spirit of the NEVYs signifies Orna Therapeutics' recognition for innovation and engagement within the biotechnology sector. Leveraging industry recognition can serve as a testament to the company's capabilities and attract potential partners or clients looking for cutting-edge solutions.
Orna Therapeutics uses 8 technology products and services including NetSuite, Google Cloud, Open Graph, and more. Explore Orna Therapeutics's tech stack below.
| Orna Therapeutics Email Formats | Percentage |
| FLast@ornatx.com | 91% |
| First.Last@ornatx.com | 8% |
| FL@ornatx.com | 1% |
Biotechnology ResearchMassachusetts, United States201-500 Employees
Orna Therapeutics is a biotechnology company reshaping RNA therapeutics. We are developing the leading circular RNA technology platform (oRNA®) and unprecedented lipid nanoparticle (LNP) delivery solutions – unlocking the therapeutic possibilities of circular RNA and pioneering the next chapter of safe and effective in vivo therapies for the treatment of disease. Website: www.ornatx.com
Company Overview
Media & News
Funding & FinancialsOrna Therapeutics has raised a total of $221M of funding over 3 rounds. Their latest funding round was raised on Aug 16, 2022 in the amount of $221M.
Orna Therapeutics's revenue is in the range of $10M$50M
Funding & FinancialsOrna Therapeutics has raised a total of $221M of funding over 3 rounds. Their latest funding round was raised on Aug 16, 2022 in the amount of $221M.
Orna Therapeutics's revenue is in the range of $10M$50M
1-888-653-2347 
support@leadiq.com